Home › Funds › Sofinnova Investments, Inc. › GMAB
Sofinnova Investments, Inc. position in GMAB
GENMAB A/S · Health Care
Sofinnova Investments, Inc. reported holding 4,045,215 shares of GMAB (GENMAB A/S) in its Q2 2026 13F filing — a position valued at US$111.1M, representing 5.92% of its reported portfolio and ranking #3 among its reported holdings. Sofinnova Investments, Inc. has disclosed GMAB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s GMAB position evolved
Sofinnova Investments, Inc. first disclosed a stake in GMAB in Q1 2026 at 752,261 shares (US$20.2M). The position peaked in Q2 2026 at 4,045,215 shares, worth US$111.1M. Across 2 filings, Sofinnova Investments, Inc. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,045,215 shares valued at US$111.1M — an increase of 3,292,954 shares quarter over quarter.. Notable position changes include a 438% increase in Q2 2026 (shares rose 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 752.26K | $20.18M | New |
| Q2 2026 | 4.05M | $111.12M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GMAB and 13F data
GMAB (GENMAB A/S) is a Health Care company. 30 other funds we track also report a position in GMAB — the largest reported positions include Paradigm Biocapital Advisors LP (US$360.8M), Orbis Allan Gray Ltd (US$312.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$188.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GMAB
- Paradigm Biocapital Advisors LP 13.13M sh · $360.77M · Q2 2026
- Orbis Allan Gray Ltd 11.37M sh · $312.28M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 6.87M sh · $188.58M · Q2 2026
- HARDING LOEVNER LP 3.09M sh · $86.90M · Q2 2026
- Deep Track Capital, LP 3.00M sh · $82.41M · Q2 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held GMAB?
Sofinnova Investments, Inc. has disclosed GMAB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Sofinnova Investments, Inc.'s current position in GMAB?
As of Q2 2026, Sofinnova Investments, Inc. holds 4.05M shares of GMAB (GENMAB A/S), valued at $111.12M, representing 5.92% of its reported portfolio and ranking #3.
Has Sofinnova Investments, Inc. been buying or selling GMAB?
In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. increased its position in GMAB. The position peaked in Q2 2026 at 4.05M shares.
Which other funds hold GMAB?
Other major institutional holders of GMAB include Paradigm Biocapital Advisors LP, Orbis Allan Gray Ltd, DEERFIELD MANAGEMENT COMPANY, L.P., among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.